EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Aortic dilatation and gastrointestinal disease: expansion of the hyperinsulinism-polycystic kidney disease phenotype

Daphne Yau, Unai Diaz-Moreno, Elena Cervi, Meera Shaunak, Ereny Bassilious, Jonathan Kraus Friedmann, Craig Jefferies, Clare Gilbert, Kate Morgan, Nicola Townsend, Stephen Marks, Jelena Stojanovic, Iona Madden, Detlef Bockenhauer, Fevronia Kiparissi, Kelsey Jones, Stephanie Grunewald, Sarah E Flanagan, Antonia Dastamani

Journal of the Endocrine Society · 2026-11-02 · 10 (12)

DOI: 10.1210/jendso/bvag243 ↗
AbstractBibliografische Angaben

Abstract

Abstract Context Congenital hyperinsulinism (HI) with polycystic kidney disease (PKD), or HIPKD, is a recently described syndrome caused by a specific promotor variant in PMM2, a gene otherwise associated with PMM2 congenital disorder of glycosylation. Objective To describe the HIPKD clinical phenotype, expanding our understanding and its distinction from the congenital disorder of glycosylation phenotype. Design Retrospective multicenter cohort study of individuals with HIPKD identified through an international HI genetic referral center. Patients Ten individuals from 9 families compound heterozygous for the promoter variant c.-167G > T and a pathogenic intragenic variant in PMM2. Intervention None. Main Outcome Measures Observed clinical features and outcomes. Results Median age of presentation was 5 months (range 0-42). Median age at follow up was 12.7 years (range 5.4-20.1). HI was managed with diazoxide monotherapy (7/10 patients), diazoxide and nifedipine (2/10 patients), and carbohydrate supplementation alone (1/10 patient). PKD age at diagnosis and severity was variable, ranging from antenatal presentation requiring renal transplantation, to incidental detection in mid-childhood. Liver cysts were noted in 6/10 patients (5/6 with normal liver function). Five of 7 patients had systemic hypertension and 3/5 were normotensive on losartan at last follow up. Inflammatory bowel disease (IBD) with gastric antral foveolar hyperplasia occurred in 4/10 patients, and aortic root and/or ascending aortic dilation in 4/7 patients who underwent echocardiography, 3 of whom also had IBD. Conclusion HIPKD due to a PMM2 promoter variant is associated with broad, multisystem phenotype, including IBD and aortic dilation. These findings support targeted screening for IBD and cardiovascular surveillance in addition to standard endocrine and renal follow up.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →